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Incubation of human platelets with cholesterol-poor, cholesterol-normal and cholesterol-rich liposomcs revealed that: (i) acquisition or depletion 
of platelet membrane cholesterol was highly selective; (ii) variation in membrane cholesterol was highly selective. Variation in membrane cholesterol 
content (cholesterol-to-phospholipid molar ratio from 0.15-I 2) with respect to values found in unmodified normal platelets. was parallrkd by the 
observed changes in amiloride-sensitive cytoplasmic pH, as well as phospholipase AZ aclivit J’, However, a decrease in cytoplasmic pH was 
accompanied by an increase in phospholipasc AZ activity; (iii) membrane cholesterol-modulated changes in intra-pladrt pH, as well as phospho- 
lipase AZ activity, was completely inhibited when platelets were pretreated with quinacrine (aspecific phospholipasc AZ inhibitor) beforeexposure 
to various types of liposomes. Although exposure of platelets (pretreated with amiloride) with various types of liposomes resulted in the inhibition 
of Na+/H’ exchange it had no noticeable ffect upon the observed phospholipasr A, activity. Based upon these results WC suggest that membrane 
cholesterol-modulated phospholipase AZ activity may be the basic mecha&m responsible for the nature of Na’lH’ exchanger activity observed 
in cholesterol-enriched platelets, leading these platelets to a hypcrsensitked state. 
Cholesterol; Na’/H’ exchange; Phospholipasc A,; Platelet 
I. INTRODUCTION 
It is now widely recognised that platelets provide an 
excellent human cellular model for the understanding of 
cellular activity modulated by second messengers. lnter- 
est in platelets has also been generated because of their 
increased sensitivity to aggregating agents in hyper- 
cholesterolemic patients [1,2]. Consequently, a series of 
in vitro studies were sought to establish the basis of this 
hypersensitivity: when the cholesterol-to-phospholipid 
(C/P) molar ratio was elevated by exposure to cholest- 
erol-rich liposomes, the platelets were found to have 
increased membrane microviscosity [3], increased sensi- 
tivity to epinephrine, ADP and thrombin [4] and in- 
creased or decreased basal activity of adenyl cyclase [5]. 
Further, stimulation of Na+/H+ exchange has been 
suggested to play a role in the activation of platelets by 
thrombin and other agonists [6-lo] and it has been 
concluded that Na*/H* exchange may selectively modu- 
late arachidonic acid mobilization in response to weak 
agonists (epinephrine, ADP and thrombin at low con- 
centrations), to effect vigorous platelet aggregation and 
dense granule secretion [8]. A role in cytoplasmic pH 
regulation has also been proposed [lo]. Consequently, 
keeping in view the complex role of membrane cholest- 
erol, as well as Na’/H+ exchange, in the activity of 
human platelets, the present study was addressed to 
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understand two specific issues: firstly, whether or not 
variation in platelet membrane cholesterol content has 
a direct effect upon the cytoplasmic pH and secondly, 
if so, whether or not membrane cholesterol-modulated 
cytoplasmic pH is mediated through phospholipase A2 
activation. 
2. MATERIALS AND METHODS 
2. I, bfurerids 
Cholesterol, ecithin, amiloride, 6-carboxyfiuorcscein d acctate and 
quinacrinc were purchased from Sigma. All other rcagcnts were of the 
highest quality available. 
2.2. Liposonu prepmarion 
‘Cholesterol-poor’, ‘diolesterol-normal’ and ‘cholcstctc!-rich’ li-
posomes, having C/P ratios equal to 0, 1 .O and 2.2, respectively, were 
made in Tyrode’s solution by employing standard methods 141. 
2.3. Pfrrteket incubulion cxperitnctlIs 
All blood donors had fasted for I2 h, had abstained from meclica- 
tion for 10 days before blood donation and had normal serum lipo- 
protein profiles according to standard criteria. Within 45 min of col- 
lection, platelet-rich plasma was adjusted to a platelet count of 3 - 4 
x 10’ per yl with platelet-poor plasma, and this mixture was incubated 
with an equal volume of cholesterol-poor, cholesterol-normal or
cholesterol-rich tiposomes in tyrode’s olution at 37% for up to S h. 
Samples were removed at various times up to 5 h for analysis of 
protein [l I], phospholipid [12] and cholesterol 1131 content of platelets. 
No platelet aggregation was observed with treatment of liposames 
with platelets in up tz 5 h of incubation, which is in agreement with 
results rcportcd by various workers [4]. From these expriments 5 
types of platelet preparations (characterized by their membrane UF 
ratio, t”Ynging from 0.15-1.2) were used for the analysis of intrd- 
platelet pH. as well as phospholipase A> activity within platelets. 
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Since the ATP release by platelets in response to various agonists 
has been shown to be directly proportional to the extent of aggrega- 
tion, the platelets enriched with cholesterol for 5 h (C/P ratio = 1.2) 
were incubated with ADP (O-IS PM), epincphrine (O-15 ,uM) and 
collagen (O-5 ygIm1). Subsequently, the ATP release was measured 
using luciferin-luciferase assay [l4]. 
25. Phosplrolipase A, activity 
Platelet preparations (C/P ratio 0.15-I .2), with or without prctreat- 
ment with quinacrine (IS0 yM), EGTA (final concentration 3m?vl) 
or amiloride (300 mM). were processed for phospholipase A2 activity 
according to the method of Wong et al. [IS]. Phospholipase Al activity 
in cholesterol-enriched platelets was also studied in the presence of 
varying concentrations ofquinacrine (O-?OOpM) or EGTA (O-3 mM). 
2.6. Na’/Fi+ exchange deterrhxion 
The activity of Na+/H+ exchangers in platelets was measured by 
monitoring intracellular pH through pH-sensitive probes generated in
situ [16]. Washed platelets in HEPES buffer, pH 7.35, were incubated 
with 6.carboxyfluorescein d acetate (25 PM of dye, final concentra- 
tion, in dimcthyl sulfoxide 0.1% final concentration) at 37’C for I5 
min and subsequently gel filtered on a Sepharose 2B column equi- 
librdtcd with HEPES buffer, pH 7.35, to remove non-internalized 
probe. These gel-filtered platelets were resuspended in platelet-poor 
plasma nd pretreated without or with either amiloride (200yM final 
concentration; a specific blocker of Na’IH’ exchange 1171) or qui- 
nacrinc (I 50 PM final concentration; a specific blocker of phospholip- 
ase A, [18]) for IS min before exposure to either cholesterol-poor, 
cholesterol-normal orcholesterol-rich liposomcs at 37OC for up to 5 
h. From these xperiments, five types of platelet preparations (charac- 
terized by their membrane C/P ratio, ranging from 0.15-1.2) were 
selected and subsequently gel-filtered again on a Scpharose 2B column 
equilibrated with NEPES buffer, pH 7.35, and fluorescence was 
measured at an emission wavelength of 518 nm corresponding to 
maximal 6-carboxy-fluorescein pH sensitivity [l9]. An aliquot of cells 
was taken immediately prior to stimulation, the platelets centrifuged, 
and the fluorescence of the supernatant measured and subtracted from 
the ccl1 suspension to correct for the prescncc of extracellular dye, 
Intracellular pH was determined from the calibration curve obtained 
with and without platelets. 
3. RESULTS 
Enrichment or depleti.on experiments employing li- 
posome technology revealed that acquisition or deple- 
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Fig. I. EtTcct of incubation of platelets with cholesterol-poor (C,), 
cholesterol-normal (C,) and cholesterol-rich (C,) liposomes in 
Tyrode’s solution on platelet choles.teroUphospholipid ratio and 
(inset) phospholipid (& and protein (m) content. Values represent 
mean of 10 subjects zt S.D. 
tion of cholesterol from platelets was highly selective 
and that there was no significant change in the phospho- 
lipid or protein content per platelet (Fig. 1) Further, 
when the cholesterol-enriched platelets were exposed to 
ADP (O-15 yM), epinephrine (O-15 yM) and collagen 
(O-5 pg/ml), there was a dose-dependent increase in 
ATP secretion by these platelets indicating hypersensi- 
tivity to these aggregating agents (Fig. 2) These results 
are in agreement with those reported by other investi- 
gators regarding the sensitivity of cholesterol-enriched 
platelets [4]. Based upon these results, five types of pla- 
telet preparations, characterized by their membrane C/P 
ratio (ranging from 0.15-l .2 M; (Fig. 1) were employed 
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Fig. 2. Effect of different concentrations of agonists on ATP release by cholesterol-enriched platelets having a membrane cholesterol-to-phospho- 
lipid ratio of 1.2 (A) ADP. (If) Epincphrine. (C) Collagen. Each value represents mean 2 S.D. of 10 subjects. Cr, cholesterol-rich; N, cholesterol- 
normal; Cp, cholesterol-poor. 
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Fig. 3. Plot of intra-platelet pN as a function of platelet membrane 
cholcstcrol-to-phospholipid ratio, ranging from 0.15-l .2 (selected 
from Fig. I). l denotes platelets without pretreatment with quinacrine 
and amiloridc; A and l denote platelets pretreated with quinacrine 
and amiloridc, respectively. Each point represents mean f SD. of 
experiments done in triplicate. 
to examine the intra-platelet pH, as well as phospholip- 
ase AZ activity, in the presence or absence of quinacrine 
(a spesific inhibitor of phospholipase AJ or amiloride 
(a specific inhibitor of Na’/H’ exchangers). The results 
of such a study (Figs. 3 and 4) revealed that, as com- 
pared to normal platelets, platelets having; (i) a C/P 
ratio of 0.2 or 0.8 exhibited a significant increase in 
phospholipase A? activity accompanied by a significant 
decrease in the intracellular pH; (ii) a C/P ratio of 0.15 
showed a slight increase in the phospholipase A, activity 
coupled with nosignificant change in intra-platelet pH; 
(iii) a C/P ratio of 1.2 showed a significant increase in 
phospholipase Al activity, as well as a slight increase in 
intra-platelet ~1% However, exposure of platelets 
(pretreated with quinacrine) to cholesterol-poor, 
cholesterol-normal or cholesterol-rich liposomes for up 
to 5 h did not result in any significant change in either 
phospholipase AZ activity or intra-platelet pH as com- 
pared to values found in normal platelets. Further, ex- 
posure of platelets (pretreated with amiloride) to 
cholesterol-poor, cholesterol-normal or cholesterol-rich 
liposomes for up to 5 h resulted in: (i) no significant 
change in the intra-platelet pH with respect o values 
found in normal platelets although the cytoplasmic pH 
shifted siightly towards the acidic region in a!1 tbc five 
types of platelet preparations examined; and (ii) no no- 
ticeable effect on the phospholipase Al activity stimu- 
lated by membrane cholesterol variation. Further, in 
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Fig. 4. Plot of phospholipase AZ (PLAJ activity as a function of 
platelet membrane cholesterol-to.phospholipid molar mtio. mnaing 
from 0.15-l 2 (selected from Fig. I). l denotes plateleta without prc- 
treatment with quinacrine, amiloridc and EGTA; G, A and I denote 
platelets pretreated with quinacrine, amiloride and ECXA, reupec- 
tively. Each point represents mean ? SD. of experiments done in 
triplicate. 
order to confirm the dose-dependent efficacy of qui- 
nacrine on phospholipase A? activity, the effect of vari- 
ous concentrations of quinacrine or EGTA upon phos- 
pholipase Al activity was also studied and the results 
unambigously depicted that membrane cholesterol- 
modulated phospholipase A2 activity was responsible 
for the observed changes in the cytoplasmic pH (Fig. 5). 
QUINACRINE [yM) 
50 700 150 200 
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EGTA (mM) 
Fig. 5. Effect of different concentrations ofquinacrine and EGTA on 
phospholipase A, activity (PLA> of cholesterol-enriched piatelets 
having a cholcstcrol-to-phospholipid ratio of 1.2.0--.O and 0-O 
denote quinacrinc and EGTA. respectively. Each value represents 
mean f S.D. of experiments done in triplicate. 
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4. DISCUSSION REFERENCES 
Patients with familial hypercholesterolemia have ele- 
vated levels of LDL and reduced plasma concentrations 
of HDL [20,21]. Platelet activity in these patients is 
elevated and this is evident with regard to platelet adhc- 
sion, aggregation, serotonin release and reduced who- 
leblood bleeding time [20,22,23]. Since platelets are cells 
without nuclei, the source of their cholesterol must be 
either the parent megakaryocyte or the plasma, through 
interaction of lipoproteins that transport cholesterol. It
is in this context hat the results reported here may be 
of some importance in understanding the role of 
membrane cholesterol in platelet activity in general and 
the hypersensitivity phenomenon in particular. The 
results reported here clearly indicate that the ‘Molecu- 
lar-switch’ through which membrane cholesterol modu- 
lates Na*/H’ exchange within platelets is phospholipase 
Al, and the ‘saw-tooth’ response curves obtained in the 
case of Na+/H’ exchange, as well as phospholipase Al 
activity as a function of increased or decreased 
membrane cholesterol content within the platelets, may 
be arising due to competition between cholesterol and 
calcium at the calcium-binding site of the phospholipase 
A7 molecule. Based upon these results it appears that 
activation of phospholipase AZ activity results in ac- 
cumulation of intra-platelet protons 1241, leading to a 
decreased cytoplasmic pH which may in turn be re- 
sponsible for the activation of Na+/H* exchangers. 
These results may also explain why platelets from hy- 
percholesterolemic patients are sensitive to various ag- 
gregating agents, because most of these agonists are 
known to interfere directly or indirectly with Na’/H’ 
exchange. In conclusion we suggest hat membrane 
cholesterol-modulated phospholipase A, activity may 
act as a molecular-switch for the regulation of Na’/H* 
exchange in cholesterol-enriched platelets. This hy- 
pothesis is in agreement with the reported findings that; 
(i) amiloride-sensitive Na’ uptake in fibroblasts was 
found to be stimulated by melittin, which is known to 
activate phospholipase A, [25,26]; and (ii) stimulation 
of Na’/H’ exchange was also reduced by long incuba- 
tion with dexamethasone, which is known to induce 
synthesis of lipomodulin, an intrinsic phospholipase in- 
hibitor [25]. 
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